MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

10/27/2014 by Brad Perriello

Sequent Medical CEO Tom Wilder tells why his company's MicroBraid technology is a key differentiator in its Web device for treating brain aneurysms and, potentially, other conditions.

Sequent Medical CEO Wilder bets on braids

Sequent Medical CEO Tom Wilder estimates that the global market for neuro-interventional devices is worth about $1.2 billion. But there's an aspect...

10/24/2014 by Brian Johnson

In this DeviceTalks preview, we catch up with Masimo CEO Joe Kiani to discuss new challenges facing the company and how medtech can break the cycle of the era of 'good-enough' innovation.

Masimo's Kiani on 'good-enough innovation,' Medtronic, Apple and 25 years of pushing the envelope

Twenty-five years have done little to diminish the fire inside Joe Kiani and Irvine, Calif. -based...

10/01/2014 by Brian Johnson

Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to about OCTANe's 2014 Medical Device Investor Forum.

OCTANe's Matthew Jenusaitis

OCTANe, the industry council responsible for promoting the innovation climate in Orange County, Calif., existed before Matthew Jenusaitis arrived, but he has put his mark on the organization's impact on one of the world's largest med tech clusters.

Jenusaitis' medtech pedigree, which includes 15 years at Boston Scientific (NYSE:...

09/24/2014 by Brad Perriello

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells

What's behind the slump in early-stage medtech investment?

It's a hard world out there for those looking to turn their cutting edge medical device ideas into commercial products, with investors shying away from...

09/03/2014 by Brad Perriello

David Green tells about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.


Last year, when Harvard Bioscience (NSDQ:HBIO) spun out its regenerative medicine business as...

08/15/2014 by Arezu Sarvestani

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp